Skip to Main content Skip to Navigation
Journal articles

Immuno-PET for Clinical Theranostic Approaches

Abstract : Recent advances in molecular characterization of tumors have allowed identification of new molecular targets on tumor cells or biomarkers. In medical practice, the identification of these biomarkers slowly but surely becomes a prerequisite before any treatment decision, leading to the concept of personalized medicine. Immuno-positron emission tomography (PET) fits perfectly with this approach. Indeed, monoclonal antibodies (mAbs) labelled with radionuclides represent promising probes for theranostic approaches, offering a non-invasive solution to assess in vivo target expression and distribution. Immuno-PET can potentially provide useful information for patient risk stratification, diagnosis, selection of targeted therapies, evaluation of response to therapy, prediction of adverse effects or for titrating doses for radioimmunotherapy. This paper reviews some aspects and recent developments in labelling methods, biological targets, and clinical data of some novel PET radiopharmaceuticals.
Document type :
Journal articles
Complete list of metadatas

Cited literature [78 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-01636873
Contributor : Elizabeth Bernardo <>
Submitted on : Friday, November 17, 2017 - 10:08:24 AM
Last modification on : Thursday, November 5, 2020 - 9:54:08 AM
Long-term archiving on: : Sunday, February 18, 2018 - 1:30:46 PM

File

BaillyIntJMolSciEq13.pdf
Files produced by the author(s)

Identifiers

Citation

Clément Bailly, Pierre-François Cléry, Alain Faivre-Chauvet, Mickael Bourgeois, François Guérard, et al.. Immuno-PET for Clinical Theranostic Approaches. International Journal of Molecular Sciences, MDPI, 2016, 18 (1), Epub ahead of print. ⟨10.3390/ijms18010057⟩. ⟨inserm-01636873⟩

Share

Metrics

Record views

414

Files downloads

425